Conserved Siglecs

What Is Conserved Siglecs?

Siglecs can be classified into many groups using various categorization criteria. For example, Siglecs can be divided into two groups CD33-Related Siglecs and conserved Siglecs, depending on how much of their sequence is conserved. The word "conserved" actually refers to the fact that conserved Siglecs have been maintained throughout evolution and are constant in rodents and humans. CD BioGlyco has established a Microarray Platform and offers Sialic Acid Microarray and Lectin Microarray Assay for customers to study conversed Siglecs.

Presence of Siglec family members in selected mammalian species.Fig.1 Presence of Siglec family members in selected mammalian species. (Bornhöfft, et al., 2018)

Conversed Siglecs Family

There are four members of the Conserved family, Siglec-1 (Sialoadhesin/ CD169), Siglec-2 (CD22), Siglec-4 (myelin-associated glycoprotein/MAG), and Siglec-15, The sequence identity between them is low. but they have clear orthologues in all mammalian species examined. Due to these Siglecs all binding to sialic acid, CD BioGlyco provides Sialic Acid Analysis Service for customers to study the ability of Siglecs to bind to sialic acid.

Roles in Biology

  • When Siglec-2 interacts with BCR, BCR signaling is suppressed. Additionally, Siglec-2 has been linked to toll-like receptor signaling, which connects innate and adaptive immune responses. Notably, Siglec-2 is a prime target for B-cell malignancies due to its restricted expression on B cells and its function in preventing BCR activation. B-cell cancers are treated with CD22-targeting CAR-T cells or CAR-T cells that simultaneously target CD19 and CD22.
  • Siglec-4 is a cell adhesion molecule that transports the carbohydrates of the human natural killer 1 (HNK-1). The anticancer efficacy of a Siglec-4-derived long spacer for CAR-T therapy is comparable to that of a CD8 spacer, but it is suggested to target membrane-proximal epitopes more effectively with reduced CNS toxicity.
  • To the sialyl-Tn structure seen in malignancies, Siglec-15 can bind. This is linked to 2,3-linked sialic acid as well as a bad prognosis in patients with ovarian, colorectal, or stomach cancer. For patients with anti-PD-1 / PD-L1 resistance, Siglec-15 is now emerging as a novel immunosuppressant because it is mutually exclusive with PD-L1.

CD BioGlyco provides excellent microarray analysis services and can customize microarrays to meet various research needs. We want to be your assistant in the field of Siglecs research, so please contact us if you are interested in our services.


  1. Bornhöfft, K.F.; et al. Siglecs: A journey through the evolution of sialic acid-binding immunoglobulin-type lectins. Developmental & Comparative Immunology. 2018, 86: 219–231.
  2. Jiang, K.Y.; et al. The intriguing roles of SIGLEC family members in the tumor microenvironment. Biomarker Research. 2022, 10(1).
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.